SPIC

Across TCGA pan-cancer cohorts, SPIC Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPIC data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPIC Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPIC expression acts as an unfavorable survival marker.

LIHC, SARC, and SKCM are the cancer types where SPIC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
SARC	OS	Median	All	0.250	0.766	.030	6	view →
SKCM	OS	Median	IV	0.589	0.754	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPIC–LIHC (DFS)

Open the LIHC breakdown →